ARK Invest's position in IAM, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 1,736,486 | $25.8M | 1.30% | #25 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-06 | ARKG | Buy | Added | 16,550 | $168K |
| 2026-11-05 | ARKG | Buy | Added | 187,816 | $2.2M |
| 2026-11-04 | ARKG | Buy | Added | 35,248 | $472K |
| 2026-11-03 | ARKG | Buy | Added | 22,226 | $300K |
| 2026-11-02 | ARKG | Buy | Added | 64,014 | $829K |
| 2026-10-22 | ARKG | Buy | Added | 6,604 | $97K |
| 2026-10-21 | ARKG | Buy | Added | 18,936 | $299K |
| 2026-10-20 | ARKG | Buy | Added | 101,248 | $1.6M |
| 2026-10-19 | ARKG | Buy | Added | 60,269 | $985K |
| 2026-10-15 | ARKG | Buy | New position | 1,184,955 | $22.4M |
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery…
See IAM's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open IAM on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.